Published in:
01-06-2010 | Clinical Investigation
Intra-arterial Methylprednisolone Infusion in Treatment-Resistant Graft-Versus-Host Disease
Authors:
Joshua L. Weintraub, Adam R. Belanger, Chris C. Sung, P. Anondo Stangl, F. Scott Nowakowski, Robert L. Lookstein
Published in:
CardioVascular and Interventional Radiology
|
Issue 3/2010
Login to get access
Abstract
Acute graft-versus-host disease (GVHD) is a potentially fatal complication following allogeneic hematopoietic stem cell transplant. Standard primary therapy for acute GVHD includes systemic steroids, often in combination with other agents. Unfortunately, primary treatment failure is common and carries a high mortality. There is no generally accepted secondary therapy for acute GVHD. Although few data on localized therapy for GVHD have been published, intra-arterial injection of high-dose corticosteroids may be a viable option. We treated 11 patients with steroid-resistant GVHD using a single administration of intra-arterial high-dose methylprednisolone. Three patients (27%) died periprocedurally. Four patients (36%) had a partial response to intra-arterial treatment and were discharged on total parenteral nutrition and oral medication. Four patients (36%) had a complete response and were discharged on oral diet and oral medication. No immediate treatment or procedure-related complications were noted. Twenty-seven percent of patients survived long-term. Our preliminary results suggest that regional intra-arterial treatment of steroid-resistant GVHD is a safe and potentially viable secondary therapy in primary treatment-resistant GVHD.